---
format: 
  html:
    include-in-header: 
      - includes/icons.html
---

::: grid
::: g-col-12
## [People]{style="color: #1E354B"}

##### PI {style="color: #7f7f7f"}
:::

::: g-col-2
![](assets/steve_profile.jpg){fig-align="center"}
:::

::: g-col-10
[**Steven Smith, PharmD, MPH**]{style="color: #1E354B"} is Interim Chair & Assistant Professor in the [Department of Pharmaceutical Outcomes & Policy](https://pop.pharmacy.ufl.edu/) ([College of Pharmacy](https://pharmacy.ufl.edu/)) and [Division of Cardiovascular Medicine](https://cardiology.medicine.ufl.edu/) ([College of Medicine](https://med.ufl.edu)) at the [University of Florida](https://www.ufl.edu/). He also serve as Co-Director for the [UF Center for Integrative Cardiovascular and Metabolic Disease](https://cicmd.center.ufl.edu/). His research methodology is fairly wide-ranging, encompassing clinical trial work and observational methods (e.g., with claims and electronic health record data), though the therapeutic focus is primarily in the field of hypertension and related cardiometabolic disease.
:::

::: g-col-12
##### Current Grad Students {style="color: #7f7f7f"}
:::

::: g-col-2
![](assets/shailina_keshwani.jpg){fig-align="center"}
:::

::: g-col-10
[**Shailina Keshwani, MS**]{style="color: #1E354B"} is a PhD student in the Department of Pharmaceutical Outcomes and Policy. Her research is focused on the intersection of pain and cardiovascular disease and specifically use of analgesics in patients with cardiovascular disease who have contraindications to such medications.
:::

::: g-col-2
![](assets/asinamai_ndai.jpg){fig-align="center"}
:::

::: g-col-10
[**Asinamai Ndai, MS**]{style="color: #1E354B"} is a PhD student in the Department of Pharmaceutical Outcomes and Policy. His research is focused on the intersection of hypertension and HIV.
:::

::: g-col-2
![](assets/kayla_smith.jpg){fig-align="center"}
:::

::: g-col-10
[**Kayla Smith, PharmD**]{style="color: #1E354B"} is a PhD student in the Department of Pharmaceutical Outcomes and Policy. She previously worked with me on several project characterizing antihypertensive use patterns during her Doctor of Pharmacy degree program.
:::

::: g-col-12
##### Research Coordinator(s) {style="color: #7f7f7f"}
:::

::: g-col-2
![](assets/Mirian-Hay-Roe.jpg){fig-align="center"}
:::

::: g-col-10
[**Mirian Hay-Roe, PhD**]{style="color: #1E354B"} is the Research Coordinator for the [UF Center for Integrative Cardiovascular and Metabolic Disease](https://cicmd.center.ufl.edu/) and basically single-handedly runs the day-to-day activities of the CICMD. She's also adjunct faculty at Sante Fe College.
:::

::: g-col-12
##### Former Lab Members {style="color: #7f7f7f"}
:::

::: g-col-2
![](assets/earl_morris.jpg){fig-align="center"}
:::

::: g-col-10
[**Earl Morris, PharmD, MPH, PhD**]{style="color: #1E354B"} is our most recent PhD grad in the Department of Pharmaceutical Outcomes and Policy. His dissertation focused on xanthine oxidase inhibitor utilization and their comparative effects on cardiovascular and related outcomes, funded by an [American Heart Association](https://www.heart.org/) Predoctoral Fellowship award. Earl is now on Faculty in the POP Department.
:::

::: g-col-2
![](assets/marta-profile-photo.jpg){fig-align="center"}
:::

::: g-col-10
[**Marta Walsh, MS**]{style="color: #1E354B"} was our data analyst from from 2021 through early 2023. She now works as a business analyst for the Mayo Clinic in Rochester, MN.
:::

::: g-col-2
![](assets/christie_monahan.jpg){fig-align="center"}
:::

::: g-col-10
[**Christie Monahan, PharmD**]{style="color: #1E354B"} was the 2021-2023 clinical postdoctoral fellow in the Departments of Pharmacotherapy and Translational Research and Community Health and Family Medicine. Her work was primarily centered on pharmacist-managed transitions of care as well as continuous glucose monitoring in patients with diabetes.
:::

::: g-col-2
![](assets/raj_desai.jpg){fig-align="center"}
:::

::: g-col-10
[**Raj Desai, PhD**]{style="color: #1E354B"} was my first PhD student in the Department of Pharmaceutical Outcomes and Policy. His work was primarily centered on use of secondary datasets (administrative claims, EHR) for studying cardiovascular outcomes and performing comparative effectiveness research in patients with complicated antihypertensive regimens. He is now an Associate - Health Economics and Outcomes Research at the Analysis Group in Boston, MA.
:::

::: g-col-2
![](assets/chris-piszczatoski.jpg){fig-align="center"}
:::

::: g-col-10
[**Chris Piszczatoski, PharmD**]{style="color: #1E354B"} was our 2019-2021 postdoctoral fellow in the Departments of Pharmacotherapy and Translational Research and Community Health and Family Medicine. He is now on staff in the UF Community Health and Family Medicine.
:::

::: g-col-2
![](assets/G_Dawwas-CROP.jpg){fig-align="center"}
:::

::: g-col-10
[**Ghadeer Dawwas, PhD**]{style="color: #1E354B"} was a postdoctoral fellow (2019-2020) in pharmacoepidemiology, with a focus on cardiometabolic outcomes of novel antidiabetic agents. She is now on faculty at Vanderbilt University.
:::

::: g-col-2
![](assets/scott_garland.jpg){fig-align="center"}
:::

::: g-col-10
[**Scott Garland, PharmD**]{style="color: #1E354B"} was our 2017-2019 postdoctoral fellow in the Departments of Pharmacotherapy and Translational Research and Community Health and Family Medicine. He is now on faculty of the FSU College of Medicine.
:::

::: g-col-2
![](assets/andrew_hwang.jpg){fig-align="center"}
:::

::: g-col-10
[**Andrew Hwang, PharmD**]{style="color: #1E354B"} was our 2015-2017 postdoctoral fellow in the Departments of Pharmacotherapy and Translational Research and Community Health and Family Medicine. He is now on faculty at the Massachusetts College of Pharmacy and Health Sciences.
:::

::: g-col-12
## [Join the Group]{style="color: #1E354B"}

See the [about page](about.qmd) for information on joining the group.
:::
:::
